drugset
drugset / Trial / NCT05337735

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

NCT05337735 ↗

Phase 2 Suspended 140 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.

Timeline

Start
2022-08-05
Primary completion
2026-12-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Vudalimab Monoclonal antibody — Intravenous

Indications

Hodgkins lymphoma cervical carcinoma high grade malignant neoplasm peritoneal mesothelioma pleural mesothelioma small cell lung carcinoma